相關主題
商品描述
This book reviews the state-of-the-art efforts to apply machine learning and AI methods for healthy aging and longevity research, diagnosis, and therapy development. The book examines the methods of machine learning and their application in the analysis of big medical data, medical images, the creation of algorithms for assessing biological age, and effectiveness of geroprotective medications.
The promises and challenges of using AI to help achieve healthy longevity for the population are manifold. This volume, written by world-leading experts working at the intersection of AI and aging, provides a unique synergy of these two highly prominent fields and aims to create a balanced and comprehensive overview of the application methodology that can help achieve healthy longevity for the population.
The book is accessible and valuable for specialists in AI and longevity research, as well as a wide readership, including gerontologists, geriatricians, medical specialists, and students from diverse fields, basic scientists, public and private research entities, and policy makers interested in potential intervention in degenerative aging processes using advanced computational tools.
作者簡介
Alexey Moskalev, PhD, is a Corresponding Member of the Russian Academy of Sciences, Doctor of Biology, the Director of the Institute of Biogerontology of Lobachevsky State University. He is a faculty member of the School of Systems Biology, George Mason University, USA. He has authored more than 100 publications in the fields of genetics of aging, longevity and radiation genetics. His research has revealed the geroprotective and synergistic effects of different inhibitors of PI3K, TOR, NF-kB, as well as identified the geroprotective effects of fucoxanthin and ibuprofen. He has contributed to the work that uncovered the mechanisms of exceptional longevity of Myotis brandtii bats and grey whale mammalian species. Having been actively involved in the Digital Ageing Atlas, Geroprotectors and DrugAge international collaborations, his research has helped build the datasets on biomarkers of aging and anti-aging drugs. He is the recipient of the 2021 Russian Research Excellence Awardin Life Sciences.
Ilia Stambler, PhD, is the Chairman and Chief Science Officer of "Vetek" (Seniority) Association - the Movement for Longevity and Quality of Life, Israel, and a researcher at the Department of Science, Technology and Society, Bar Ilan University, Israel. His research has focused on the historical and social implications of aging and life extension research and mathematical modeling of aging and aging-related diseases. He is actively involved in advocacy for aging and longevity research, serving as an executive committee member of the International Society on Aging and Disease and International Longevity Alliance, trustee and director of the Biogerontology Research Foundation, fellow and policy director at the Global Healthspan Policy Institute. He has published over 60 academic journal articles and book chapters and has authored two books on aging and longevity. He was an active player in the campaign for the inclusion of aging into the 2017 WHO work program, and for establishing the section on "research, development and education for healthy longevity" in the Israel National Masterplan on Aging in 2019.
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine, a leader in next-generation generative artificial intelligence technologies for drug discovery and biomarker development. Under his leadership, Insilico raised over $400 million in multiple rounds from expert investors, opened R&D centers in six countries or regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions, nominated 11 preclinical candidates, and entered human clinical trials with AI-discovered novel target and AI-designed novel molecule. Since 2015 he has invented critical technologies in the field of generative artificial intelligence and reinforcement learning (RL) for generation of novel molecular structures with the desired properties and generation of synthetic biological and patient data. Since 2012 hepublished over 160 peer-reviewed research papers and two books. He founded and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (9th annual in 2022), the world's largest event on aging in the pharmaceutical industry. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
作者簡介(中文翻譯)
亞歷克謝·莫斯卡列夫（Alexey Moskalev），博士，是俄羅斯科學院的通訊成員，生物學博士，洛巴切夫斯基國立大學生物老化研究所所長。他是美國喬治梅森大學系統生物學學院的教職員。他在老化基因學、長壽和輻射基因學領域發表了超過100篇論文。他的研究揭示了不同PI3K、TOR、NF-kB抑制劑的抗老化和協同效應，並確定了褐藻黃素和布洛芬的抗老化效果。他對揭示Brandt's bat和灰鯨等哺乳動物的非凡長壽機制的研究做出了貢獻。他積極參與數位老化圖譜、抗老化劑和DrugAge等國際合作，並幫助建立了有關老化生物標記和抗老化藥物的數據集。他是2021年俄羅斯生命科學研究卓越獎的獲得者。
伊利亞·斯坦布勒（Ilia Stambler），博士，是以色列「Vetek」（Seniority）協會的主席和首席科學官，該協會致力於長壽和生活品質的運動，同時也是以色列巴爾伊蘭大學科學、技術與社會系的研究員。他的研究專注於老化和生命延長研究的歷史和社會影響，以及老化和與老化相關疾病的數學建模。他積極參與老化和長壽研究的倡導，擔任國際老化與疾病學會和國際長壽聯盟的執行委員會成員，生物老化研究基金會的受託人和董事，全球健康壽命政策研究所的研究員和政策主任。他已發表超過60篇學術期刊文章和書籍章節，並撰寫了兩本有關老化和長壽的書籍。他在2017年WHO工作計劃中推動老化納入的運動中扮演了積極角色，並於2019年促成以色列國家老化總體規劃中建立「健康長壽的研究、發展和教育」部分。
亞歷克斯·扎沃羅諾科夫（Alex Zhavoronkov），博士，是Insilico Medicine的創始人兼首席執行官，該公司是藥物發現和生物標記開發的下一代生成式人工智慧技術的領導者。在他的領導下，Insilico在多輪融資中籌集了超過4億美元，並在六個國家或地區開設了研發中心，與多家製藥、生物技術和學術機構建立了合作關係，提名了11個臨床前候選藥物，並進入了AI發現的新靶點和AI設計的新分子的臨床試驗。自2015年以來，他在生成式人工智慧和強化學習（RL）領域發明了關鍵技術，用於生成具有所需特性的新的分子結構以及合成生物和患者數據。自2012年以來，他已發表超過160篇經同行評審的研究論文和兩本書籍。他創立並共同主持了年度老化研究、藥物發現和AI論壇（2022年第九屆），這是全球製藥行業中最大的老化相關活動。他是巴克老化研究所的人工智慧兼任教授。
